{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:39:58Z","timestamp":1782254398796,"version":"3.54.5"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["17H04243"],"award-info":[{"award-number":["17H04243"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H05203"],"award-info":[{"award-number":["19H05203"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20dm0107119"],"award-info":[{"award-number":["JP20dm0107119"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00406-020-01231-x","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T19:09:53Z","timestamp":1609873793000},"page":"249-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-0439","authenticated-orcid":false,"given":"Kenji","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"1231_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbi.2020.04.046","volume":"87","author":"J Zhang","year":"2020","unstructured":"Zhang J, Xie B, Hashimoto K (2020) Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun 87:59\u201373","journal-title":"Brain Behav Immun"},{"key":"1231_CR2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jama.2019.20153","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323:1824\u20131836","journal-title":"JAMA"},{"key":"1231_CR3","doi-asserted-by":"publisher","first-page":"173646","DOI":"10.1016\/j.ejphar.2020.173646","volume":"24","author":"M Zhao","year":"2020","unstructured":"Zhao M, Zhang J, Li H, Luo Z, Ye J, Xu Y, Wang Z, Ye D, Liu J, Li D, Wang M, Wan J (2020) Recent progress of antiviral therapy for coronavirus disease 2019. Eur J Pharmacol 24:173646. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173646","journal-title":"Eur J Pharmacol"},{"key":"1231_CR4","first-page":"2239","volume":"323","author":"J Abbasi","year":"2020","unstructured":"Abbasi J (2020) Existing drugs might treat COVID-19. JAMA 323:2239","journal-title":"JAMA"},{"key":"1231_CR5","first-page":"928","volume":"324","author":"J Abbasi","year":"2020","unstructured":"Abbasi J (2020) Drug repurposing study pinpoints potential COVID-19 antivirals. JAMA 324:928","journal-title":"JAMA"},{"key":"1231_CR6","doi-asserted-by":"publisher","first-page":"13093","DOI":"10.1038\/s41598-020-70143-6","volume":"10","author":"F Touret","year":"2020","unstructured":"Touret F, Gilles M, Barral K, Nougair\u00e8de A, van Helden J, Decroly E, de Lamballerie X, Coutard B (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep 10:13093","journal-title":"Sci Rep"},{"key":"1231_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/med.21728","volume":"41","author":"X Wang","year":"2021","unstructured":"Wang X, Guan Y (2021) COVID-19 drug repurposing: a review of computational screening methods, clinical trials, and protein interaction assays. Med Res Rev 41:5\u201328","journal-title":"Med Res Rev"},{"key":"1231_CR8","first-page":"e667","volume":"2","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Wang F, Tang J, Nussinov R, Cheng F (2020) Artificial intelligence in COVID-19 drug repurposing. Lancet 2:e667\u2013e676","journal-title":"Lancet"},{"key":"1231_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbi.2020.03.031","volume":"87","author":"Y Wu","year":"2020","unstructured":"Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 87:18\u201322","journal-title":"Brain Behav Immun"},{"key":"1231_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2215-0366(20)30203-0","volume":"7","author":"JP Rogers","year":"2020","unstructured":"Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G, David AS (2020) Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 7:611\u2013627","journal-title":"Lancet Psychiatry"},{"key":"1231_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S1474-4422(20)30221-0","volume":"19","author":"MA Ellul","year":"2020","unstructured":"Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T (2020) Neurological associations of COVID-19. Lancet Neurol 19:767\u2013783","journal-title":"Lancet Neurol"},{"key":"1231_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bbi.2020.05.075","volume":"88","author":"J Zhang","year":"2020","unstructured":"Zhang J, Xu D, Xie B, Zhang Y, Huang H, Liu H, Chen H, Sun Y, Shang Y, Hashimoto K, Yuan S (2020) Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: a retrospective cohort study. Brain Behav Immun 88:50\u201358","journal-title":"Brain Behav Immun"},{"key":"1231_CR13","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1001\/jamaneurol.2020.2065","volume":"77","author":"AS Zubair","year":"2020","unstructured":"Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S (2020) Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 77:1018\u20131027","journal-title":"JAMA Neurol"},{"key":"1231_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00406-020-01148-5","volume":"2","author":"K Hashimoto","year":"2020","unstructured":"Hashimoto K (2020) Risk of neuropsychiatric disorders in offspring of COVID-19-infected pregnant women and nutritional intervention. Eur Arch Psychiatry Clin Neurosci 2:1\u20133. https:\/\/doi.org\/10.1007\/s00406-020-01148-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1231_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.10.024","author":"A Zimmer","year":"2020","unstructured":"Zimmer A, Youngblood A, Adnane A, Miller BJ, Goldsmith DR (2020) Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: a review of the literature and recommendations for the COVID-19 pandemic. Brain Behav Immun. https:\/\/doi.org\/10.1016\/j.bbi.2020.10.024","journal-title":"Brain Behav Immun"},{"key":"1231_CR16","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2020.22760","volume":"324","author":"E Lenze","year":"2020","unstructured":"Lenze E, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM (2020) Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19. A randomized clinical trial. JAMA 324:2292\u20132300","journal-title":"JAMA"},{"key":"1231_CR17","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1001\/jama.2020.21720","volume":"324","author":"CW Seymour","year":"2020","unstructured":"Seymour CW, Bauchner H, Golub RM (2020) COVID-19 infection\u2014preventing clinical deterioration. JAMA 324:2300","journal-title":"JAMA"},{"key":"1231_CR18","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.it.2020.10.004","volume":"41","author":"AG Harrison","year":"2020","unstructured":"Harrison AG, Lin T, Wang P (2020) Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trend Immunol 41:1100\u20131115","journal-title":"Trend Immunol"},{"key":"1231_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-020-10197-8","volume":"1","author":"M Santerre","year":"2020","unstructured":"Santerre M, Arjona SP, Allen CN, Shcherbik N, Sawaya BE (2020) Why do SARS-CoV-2 NSPs rush to the ER? J Neurol 1:1\u201310. https:\/\/doi.org\/10.1007\/s00415-020-10197-8","journal-title":"J Neurol"},{"key":"1231_CR20","doi-asserted-by":"publisher","first-page":"117842","DOI":"10.1016\/j.lfs.2020.117842","volume":"255","author":"A Banerjee","year":"2020","unstructured":"Banerjee A, Czinn SJ, Reiter RJ, Blanchard TG (2020) Crosstalk between endoplasmic reticulum stress and anti-viral activities: a novel therapeutic target for COVID-19. Life Sci 255:117842","journal-title":"Life Sci"},{"key":"1231_CR21","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3389\/fphar.2020.01095","volume":"11","author":"T Aoe","year":"2020","unstructured":"Aoe T (2020) Pathological aspects of COVID-19 as a conformational disease and the use of pharmacological chaperones as a potential therapeutic strategy. Front Pharmacol 11:1096","journal-title":"Front Pharmacol"},{"key":"1231_CR22","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.21873\/invivo.11956","volume":"34","author":"A K\u00f6seler","year":"2020","unstructured":"K\u00f6seler A, Sabirli R, G\u00f6ren T, T\u00fcrk\u00e7\u00fcer I, Kurt \u00d6 (2020) Endoplasmic reticulum stress markers in SARS-COV-2 infection and pneumonia: case control study. In Vivo 34:1645\u20131650","journal-title":"In Vivo"},{"key":"1231_CR23","doi-asserted-by":"publisher","first-page":"173288","DOI":"10.1016\/j.ejphar.2020.173288","volume":"882","author":"A Sureda","year":"2020","unstructured":"Sureda A, Alizadeh J, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Jeandet P, \u0141os MJ, Clementi E, Nabavi SM, Ghavami S (2020) Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? Eur J Pharmacol 882:173288","journal-title":"Eur J Pharmacol"},{"key":"1231_CR24","first-page":"517","volume":"197","author":"WR Martin","year":"1976","unstructured":"Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517\u2013532","journal-title":"J Pharmacol Exp Ther"},{"key":"1231_CR25","first-page":"284","volume":"223","author":"TP Su","year":"1982","unstructured":"Su TP (1982) Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 223:284\u2013290","journal-title":"J Pharmacol Exp Ther"},{"key":"1231_CR26","doi-asserted-by":"publisher","first-page":"8072","DOI":"10.1073\/pnas.93.15.8072","volume":"93","author":"M Hanner","year":"1997","unstructured":"Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H (1997) Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 93:8072\u20138077","journal-title":"Proc Natl Acad Sci USA"},{"key":"1231_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","volume":"131","author":"T Hayashi","year":"2007","unstructured":"Hayashi T, Su TP (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 131:596\u2013610","journal-title":"Cell"},{"key":"1231_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1517\/14728222.2011.560837","volume":"15","author":"T Hayashi","year":"2011","unstructured":"Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP (2011) Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 15:557\u2013577","journal-title":"Expert Opin Ther Targets"},{"key":"1231_CR29","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.1073\/pnas.1705154114","volume":"114","author":"A Alon","year":"2017","unstructured":"Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, Kruse AC (2017) Identification of the gene that codes for the \u03c32 receptor. Proc Natl Acad Sci USA 114:7160\u20137165","journal-title":"Proc Natl Acad Sci USA"},{"key":"1231_CR30","first-page":"3857","volume":"12","author":"K Hashimoto","year":"2006","unstructured":"Hashimoto K, Ishiwata K (2006) Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 12:3857\u20133876","journal-title":"Curr Pharm Des"},{"key":"1231_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14728222.12.1.45","volume":"12","author":"T Hayashi","year":"2008","unstructured":"Hayashi T, Su TP (2008) An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma-1 receptor ligand. Expert Opin Ther Targets 12:45\u201358","journal-title":"Expert Opin Ther Targets"},{"key":"1231_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/1871524910909030197","volume":"9","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K (2009) Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 9:197\u2013204","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"1231_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2174\/138161212799436476","volume":"18","author":"T Niitsu","year":"2012","unstructured":"Niitsu T, Iyo M, Hashimoto K (2012) Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pham Des 18:875\u2013883","journal-title":"Curr Pham Des"},{"key":"1231_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.09.001","volume":"100","author":"K Hashimoto","year":"2013","unstructured":"Hashimoto K (2013) Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 100:15\u201329","journal-title":"Prog Neurobiol"},{"key":"1231_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jphs.2014.11.010","volume":"127","author":"K Hashimoto","year":"2015","unstructured":"Hashimoto K (2015) Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharmacol Sci 127:6\u20139","journal-title":"J Pharmacol Sci"},{"key":"1231_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-3-319-50174-1_11","volume":"964","author":"Y Albayrak","year":"2017","unstructured":"Albayrak Y, Hashimoto K (2017) Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders. Adv Exp Med Biol 964:153\u2013161","journal-title":"Adv Exp Med Biol"},{"key":"1231_CR37","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.tips.2019.07.006","volume":"40","author":"HR Schmidt","year":"2019","unstructured":"Schmidt HR, Kruse AC (2019) The molecular function of \u03c3 receptors: past, present, and future. Trends Pharmacol Sci 40:636\u2013654","journal-title":"Trends Pharmacol Sci"},{"key":"1231_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3389\/fnins.2019.00761","volume":"13","author":"TP Su","year":"2019","unstructured":"Su TP (2019) Non-canonical targets mediating the action of drugs of abuse: cocaine at the sigma-1 receptor as an example. Front Neurosci 13:761","journal-title":"Front Neurosci"},{"key":"1231_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17460441.2021.1838483","volume":"27","author":"T Maurice","year":"2020","unstructured":"Maurice T (2020) Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov 27:1\u201317. https:\/\/doi.org\/10.1080\/17460441.2021.1838483","journal-title":"Expert Opin Drug Discov"},{"key":"1231_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-020-00983-3","author":"S Couly","year":"2020","unstructured":"Couly S, Goguadze N, Yasui Y, Kimura Y, Wang SM, Sharikadze N, Wu HE, Su TP (2020) Knocking out sigma-1 receptors reveals diverse health problems. Cell Mol Neurobiol. https:\/\/doi.org\/10.1007\/s10571-020-00983-3","journal-title":"Cell Mol Neurobiol"},{"key":"1231_CR41","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O\u2019Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, H\u00fcttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O\u2019Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d\u2019Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, Garc\u00eda-Sastre A, Shokat KM, Shoichet BK, Krogan NJ (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459\u2013468","journal-title":"Nature"},{"key":"1231_CR42","doi-asserted-by":"publisher","first-page":"eabe9403","DOI":"10.1126\/science.abe9403","volume":"370","author":"DE Gordon","year":"2020","unstructured":"Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Jureka AS, Obernier K, Guo JZ, Batra J, Kaake RM, Weckstein AR, Owens TW, Gupta M, Pourmal S, Titus EW, Cakir M, Soucheray M, McGregor M, Cakir Z, Jang G, O\u2019Meara MJ, Tummino TA, Zhang Z, Foussard H, Rojc A, Zhou Y, Kuchenov D, H\u00fcttenhain R, Xu J, Eckhardt M, Swaney DL, Fabius JM, Ummadi M, Tutuncuoglu B, Rathore U, Modak M, Haas P, Haas KM, Naing ZZC, Pulido EH, Shi Y, Barrio-Hernandez I, Memon D, Petsalaki E, Dunham A, Marrero MC, Burke D, Koh C, Vallet T, Silvas JA, Azumaya CM, Billesb\u00f8lle C, Brilot AF, Campbell MG, Diallo A, Dickinson MS, Diwanji D, Herrera N, Hoppe N, Kratochvil HT, Liu Y, Merz GE, Moritz M, Nguyen HC, Nowotny C, Puchades C, Rizo AN, Schulze-Gahmen U, Smith AM, Sun M, Young ID, Zhao J, Asarnow D, Biel J, Bowen A, Braxton JR, Chen J, Chio CM, Chio US, Deshpande I, Doan L, Faust B, Flores S, Jin M, Kim K, Lam VL, Li F, Li J, Li YL, Li Y, Liu X, Lo M, Lopez KE, Melo AA, Moss FR 3rd, Nguyen P, Paulino J, Pawar KI, Peters JK, Pospiech TH Jr, Safari M, Sangwan S, Schaefer K, Thomas PV, Thwin AC, Trenker R, Tse E, Tsui TKM, Wang F, Whitis N, Yu Z, Zhang K, Zhang Y, Zhou F, Saltzberg D, QCRG Structural Biology Consortium, Hodder AJ, Shun-Shion AS, Williams DM, White KM, Rosales R, Kehrer T, Miorin L, Moreno E, Patel AH, Rihn S, Khalid MM, Vallejo-Gracia A, Fozouni P, Simoneau CR, Roth TL, Wu D, Karim MA, Ghoussaini M, Dunham I, Berardi F, Weigang S, Chazal M, Park J, Logue J, McGrath M, Weston S, Haupt R, Hastie CJ, Elliott M, Brown F, Burness KA, Reid E, Dorward M, Johnson C, Wilkinson SG, Geyer A, Giesel DM, Baillie C, Raggett S, Leech H, Toth R, Goodman N, Keough KC, Lind AL, Zoonomia Consortium, Klesh RJ, Hemphill KR, Carlson-Stevermer J, Oki J, Holden K, Maures T, Pollard KS, Sali A, Agard DA, Cheng Y, Fraser JS, Frost A, Jura N, Kortemme T, Manglik A, Southworth DR, Stroud RM, Alessi DR, Davies P, Frieman MB, Ideker T, Abate C, Jouvenet N, Kochs G, Shoichet B, Ott M, Palmarini M, Shokat KM, Garc\u00eda-Sastre A, Rassen JA, Grosse R, Rosenberg OS, Verba KA, Basler CF, Vignuzzi M, Peden AA, Beltrao P, Krogan NJ (2020) Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370:eabe9403","journal-title":"Science"},{"key":"1231_CR43","doi-asserted-by":"publisher","first-page":"5618","DOI":"10.1073\/pnas.81.17.5618","volume":"81","author":"SW Tam","year":"1984","unstructured":"Tam SW, Cook L (1984) \u03c3 opiates and certain antipsychotic drugs mutually inhibit (+)-[3H]SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618\u20135621","journal-title":"Proc Natl Acad Sci USA"},{"key":"1231_CR44","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/d41587-020-00013-z","volume":"38","author":"C Harrison","year":"2020","unstructured":"Harrison C (2020) Drug researchers pursue new lines of attack against COVID-19. Nat Biotechnol 38:655\u2013664","journal-title":"Nat Biotechnol"},{"key":"1231_CR45","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/JCP.0b013e31828ea95c","volume":"33","author":"M Iyo","year":"2013","unstructured":"Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, Hashimoto K (2013) Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol 33:398\u2013404","journal-title":"J Clin Psychopharmacol"},{"key":"1231_CR46","doi-asserted-by":"publisher","first-page":"PL285","DOI":"10.1016\/0024-3205(93)90588-T","volume":"53","author":"S Okuyama","year":"1993","unstructured":"Okuyama S, Imagawa Y, Ogawa S, Araki H, Ajima A, Tanaka M, Muramatsu M, Nakazato A, Yamaguchi K, Yoshida M, Otomo S (1993) NE-100, a novel sigma receptor ligand: in vivo tests. Life Sci 53:PL285\u2013PL290","journal-title":"Life Sci"},{"key":"1231_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0014-2999(96)00254-3","volume":"307","author":"N Narita","year":"1996","unstructured":"Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996) Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307:117\u2013119","journal-title":"Eur J Pharmacol"},{"key":"1231_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2014.01.064","volume":"727","author":"T Ishima","year":"2014","unstructured":"Ishima T, Fujita Y, Hashimoto K (2014) Interactions of new antidepressants with sigma-1 receptor chaperons and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol 727:167\u2013173","journal-title":"Eur J Pharmacol"},{"key":"1231_CR49","doi-asserted-by":"publisher","first-page":"e2558","DOI":"10.1371\/journal.pone.0002558","volume":"3","author":"T Nishimura","year":"2008","unstructured":"Nishimura T, Ishima T, Iyo M, Hashimoto K (2008) Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE 3:e2558","journal-title":"PLoS ONE"},{"key":"1231_CR50","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/sj.npp.1301047","volume":"32","author":"K Hashimoto","year":"2007","unstructured":"Hashimoto K, Fujita Y, Iyo M (2007) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 32:514\u2013521","journal-title":"Neuropsychopharmacology"},{"key":"1231_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/1874241600902010007","volume":"2","author":"T Ishima","year":"2009","unstructured":"Ishima T, Fujita Y, Kohno M, Kunitachi S, Horio M, Takatsu Y, Minase T, Iyo M, Hashimoto K (2009) Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J 2:7\u201311","journal-title":"Open Clin Chem J"},{"key":"1231_CR52","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.pnpbp.2008.01.005","volume":"32","author":"M Iyo","year":"2008","unstructured":"Iyo M, Shirayama Y, Watanabe H, Fujisaki M, Miyatake R, Fukami G, Shiina A, Nakazato M, Shiraishi T, Ookami T, Hashimoto K (2008) Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:1072\u20131073","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1231_CR53","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.pnpbp.2010.06.007","volume":"34","author":"T Niitsu","year":"2010","unstructured":"Niitsu T, Shirayama Y, Fujisaki M, Hashimoto K, Iyo M (2010) Fluvoxamine improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34:1345\u20131346","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1231_CR54","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/JCP.0b013e3182664cfc","volume":"32","author":"T Niitsu","year":"2012","unstructured":"Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M (2012) A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol 32:593\u2013601","journal-title":"J Clin Psychopharmacol"},{"key":"1231_CR55","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00406-013-0406-3","volume":"263","author":"T Kishi","year":"2013","unstructured":"Kishi T, Hirota T, Iwata N (2013) Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials. Eur Arch psychiatry Clin Neurosci 263:633\u2013641","journal-title":"Eur Arch psychiatry Clin Neurosci"},{"key":"1231_CR56","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.biopsych.2007.04.001","volume":"62","author":"M Ishikawa","year":"2007","unstructured":"Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K (2007) High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry 62:878\u2013883","journal-title":"Biol Psychiatry"},{"key":"1231_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/hup.1106","volume":"25","author":"I Hindmarch","year":"2010","unstructured":"Hindmarch I, Hashimoto K (2010) Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol 25:193\u2013200","journal-title":"Hum Psychopharmacol"},{"key":"1231_CR58","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1744-859X-9-18","volume":"9","author":"T Furuse","year":"2010","unstructured":"Furuse T, Hashimoto K (2010) Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases. Ann Gen Psychiatry 9:18","journal-title":"Ann Gen Psychiatry"},{"key":"1231_CR59","doi-asserted-by":"publisher","first-page":"eaau5266","DOI":"10.1126\/scitranslmed.aau5266","volume":"11","author":"DA Rosen","year":"2019","unstructured":"Rosen DA, Seki SM, Fern\u00e1ndez-Casta\u00f1eda A, Beiter RM, Eccles JD, Woodfolk JA, Gaultier A (2019) Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med 11:eaau5266","journal-title":"Sci Transl Med"},{"key":"1231_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0304-3940(98)00943-4","volume":"260","author":"K Kato","year":"1999","unstructured":"Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M (1999) TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 260:5\u20138","journal-title":"Neurosci Lett"},{"key":"1231_CR61","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.pnpbp.2008.06.011","volume":"32","author":"T Ishima","year":"2008","unstructured":"Ishima T, Nishimura T, Iyo M, Hashimoto K (2008) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 32:1656\u20131659","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1231_CR62","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.brainres.2009.05.004","volume":"1279","author":"S Kunitachi","year":"2009","unstructured":"Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibuchi Y, Shirayama Y, Iyo M, Hashimoto K (2009) Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res 1279:189\u2013196","journal-title":"Brain Res"},{"key":"1231_CR63","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1017\/S1461145709990204","volume":"12","author":"M Ishikawa","year":"2009","unstructured":"Ishikawa M, Sakata M, Ishii K, Kimura Y, Oda K, Toyohara J, Wu J, Ishiwata K, Iyo M, Hashimoto K (2009) High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol 12:1127\u20131131","journal-title":"Int J Neuropsychopharmacol"},{"key":"1231_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0014-2999(93)90241-9","volume":"236","author":"K Hashimoto","year":"1993","unstructured":"Hashimoto K, London ED (1993) Further characterization of [3H]ifenprodil binding to sigma receptors in rat brain. Eur J Pharmacol 236:159\u2013163","journal-title":"Eur J Pharmacol"},{"key":"1231_CR65","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0922-4106(94)90211-9","volume":"266","author":"K Hashimoto","year":"1994","unstructured":"Hashimoto K, Mantione CR, Spada MR, Neumeyer JL, London ED (1994) Further characterization of [3H]ifenprodil binding in rat brain. Eur J Pharmacol 266:67\u201377","journal-title":"Eur J Pharmacol"},{"key":"1231_CR66","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0014-2999(94)00763-W","volume":"273","author":"K Hashimoto","year":"1995","unstructured":"Hashimoto K, London ED (1995) Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors. Eur J Pharmacol 273:307\u2013310","journal-title":"Eur J Pharmacol"},{"key":"1231_CR67","doi-asserted-by":"publisher","first-page":"e37989","DOI":"10.1371\/journal.pone.0037989","volume":"7","author":"T Ishima","year":"2012","unstructured":"Ishima T, Hashimoto K (2012) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: role of sigma-1 receptor and IP3 receptor. PLoS ONE 7:e37989","journal-title":"PLoS ONE"},{"key":"1231_CR68","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.biopsych.2011.10.014","volume":"71","author":"A Kishimoto","year":"2012","unstructured":"Kishimoto A, Kaneko M, Gotoh Y, Hashimoto K (2012) Ifenprodil for the treatment of flashbacks in female posttraumatic stress disorder patients with a history of childhood sexual abuse. Biol Psychiatry 71:e7\u2013e8","journal-title":"Biol Psychiatry"},{"key":"1231_CR69","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000348585","volume":"82","author":"T Sasaki","year":"2013","unstructured":"Sasaki T, Hashimoto K, Okawada K, Tone J, Machizawa A, Tano A, Nakazato M, Iyo M (2013) Ifenprodil for the treatment of flashbacks in adolescent female posttraumatic stress disorder patients with a history of abuse. Psychother Psychosom 82:344\u2013345","journal-title":"Psychother Psychosom"},{"key":"1231_CR70","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00213-013-3092-y","volume":"227","author":"K Hashimoto","year":"2013","unstructured":"Hashimoto K, Sasaki T, Kishimoto A (2013) Old drug ifenprodil, new hope for PTSD with a history of childhood abuse. Psychopharmacology 227:375\u2013376","journal-title":"Psychopharmacology"},{"key":"1231_CR71","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0014-2999(96)00201-4","volume":"306","author":"K Matsuno","year":"1996","unstructured":"Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S (1996) Binding properties of SA4503, a novel and selective sigma-1 receptor agonist. Eur J Pharmacol 306:271\u2013279","journal-title":"Eur J Pharmacol"},{"issue":"Pt 3","key":"1231_CR72","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/brain\/awq367","volume":"134","author":"K Ruscher","year":"2011","unstructured":"Ruscher K, Shamloo M, Rickhag M, Ladunga I, Soriano L, Gisselsson L, Toresson H, Ruslim-Litrus L, Oksenberg D, Urfer R, Johansson BB, Nikolich K, Wieloch T (2011) The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain 134(Pt 3):732\u2013746","journal-title":"Brain"},{"key":"1231_CR73","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1161\/STROKEAHA.114.005835","volume":"45","author":"R Urfer","year":"2014","unstructured":"Urfer R, Moebius HJ, Skoloudik D, Santamarina E, Sato W, Mita S, Muir KW, Cutamesine Stroke Recovery Study Group (2014) Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke. Stroke 45:3304\u20133310","journal-title":"Stroke"},{"key":"1231_CR74","doi-asserted-by":"publisher","first-page":"582310","DOI":"10.3389\/fphar.2020.582310","volume":"11","author":"JM Vela","year":"2020","unstructured":"Vela JM (2020) Repurposing sigma-1 receptor ligands for COVID-19 therapy? Front Pharmacol 11:582310","journal-title":"Front Pharmacol"},{"key":"1231_CR75","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","volume":"113","author":"EF Domino","year":"2010","unstructured":"Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678\u2013684","journal-title":"Anesthesiology"},{"key":"1231_CR76","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","volume":"19","author":"K Zhang","year":"2020","unstructured":"Zhang K, Hashimoto K (2020) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Opin Neurother 19:83\u201392","journal-title":"Expert Opin Neurother"},{"key":"1231_CR77","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/pcn.12902","volume":"73","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci 73:613\u2013627","journal-title":"Psychiatry Clin Neurosci"},{"key":"1231_CR78","doi-asserted-by":"publisher","first-page":"113935","DOI":"10.1016\/j.bcp.2020.113935","volume":"177","author":"K Hashimoto","year":"2020","unstructured":"Hashimoto K (2020) Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol 177:113935","journal-title":"Biochem Pharmacol"},{"key":"1231_CR79","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.euroneuro.2011.08.002","volume":"22","author":"MJ Robson","year":"2012","unstructured":"Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR (2012) Evaluation of sigma (\u03c3) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol 22:308\u2013317","journal-title":"Eur Neuropsychopharmacol"},{"key":"1231_CR80","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.biopsych.2014.06.021","volume":"77","author":"JJ Yang","year":"2015","unstructured":"Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K (2015) Serum interleukin-6 is a predictive biomarker for ketamine\u2019s antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry 77:e19\u2013e20","journal-title":"Biol Psychiatry"},{"key":"1231_CR81","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1053\/j.jvca.2020.04.037","volume":"34","author":"J Ortoleva","year":"2020","unstructured":"Ortoleva J (2020) Consider adjunctive ketamine in mechanically ventilated coronavirus disease-2019 patients. J Cardiothorac Vasc Anesth 34:2580","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"1231_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26681","author":"K Akinosoglou","year":"2020","unstructured":"Akinosoglou K, Gogos A, Papageorgiou C, Angelopoulos E, Gogos C (2020) Ketamine in COVID-19 patients: Thinking out of the box. J Med Virol. https:\/\/doi.org\/10.1002\/jmv.26681","journal-title":"J Med Virol"},{"key":"1231_CR83","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/0014-2999(90)90379-K","volume":"187","author":"P Klepstad","year":"1990","unstructured":"Klepstad P, Maurset A, Moberg ER, Oye I (1990) Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 187:513\u2013518","journal-title":"Eur J Pharmacol"},{"key":"1231_CR84","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1600-0773.1995.tb01041.x","volume":"77","author":"O Hustveit","year":"1995","unstructured":"Hustveit O, Maurset A, Oye I (1995) Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 77:355\u2013359","journal-title":"Pharmacol Toxicol"},{"key":"1231_CR85","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.neuint.2008.04.010","volume":"53","author":"R Kortekaas","year":"2008","unstructured":"Kortekaas R, Maguire RP, van Waarde A, Leenders KL, Elsinga PH (2008) Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptors\u2014the cases of ketamine and haloperidol. Neurochem Int 53:45\u201350","journal-title":"Neurochem Int"},{"key":"1231_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-020-01110-5","author":"GC Leal","year":"2020","unstructured":"Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda ALT, Quarantini LC (2020) Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-020-01110-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1231_CR87","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70:621\u2013660","journal-title":"Pharmacol Rev"},{"key":"1231_CR88","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jocn.2020.08.014","volume":"80","author":"UH Yesilkaya","year":"2020","unstructured":"Yesilkaya UH, Balcioglu YH, Sahin S (2020) Reissuing the sigma receptors for SARS-CoV-2. J Clin Neurosci 80:72\u201373","journal-title":"J Clin Neurosci"},{"key":"1231_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(20)30462-4","author":"M Taquet","year":"2020","unstructured":"Taquet M, Luciano S, Geddes JR, Harrison P (2020) Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. Lancet Psychiatry. https:\/\/doi.org\/10.1016\/S2215-0366(20)30462-4","journal-title":"Lancet Psychiatry"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-020-01231-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-020-01231-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-020-01231-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T16:03:11Z","timestamp":1674835391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-020-01231-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1231"],"URL":"https:\/\/doi.org\/10.1007\/s00406-020-01231-x","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]},"assertion":[{"value":"24 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Hashimoto is the inventor of filed patent applications on \u201cThe use of <i>R<\/i>-ketamine in the treatment of psychiatric diseases\u201d, \u201c(<i>S<\/i>)-norketamine and salt thereof as pharmaceutical\u201d, \u201c<i>R<\/i>-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder\u201d, \u201cPreventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases\u201d, and \u201c<i>R<\/i>-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder\u201d by the Chiba University. Dr. Hashimoto received speaker honoraria from Abbott China. Dr. Hashimoto has received the research support from Dainippon Sumitomo, Otsuka, and Taisho.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}